Page 3 - Anjali Singh

Global pharma uses AI to speed drug timelines, but adoption remains uneven

Pharma leaders at BioAsia said AI is accelerating discovery and documentation, doubling pipelines at some firms, though its impact on clinical costs and timelines remains uneven

Hyderabad strengthens role as MNC hub for AI, life sciences and GCC growth

Global firms are scaling AI, life sciences and GCC operations in Hyderabad, backed by strong talent, pharma depth and policy support, with major investments announced around BioAsia this week

Sanofi scales up Hyd hub, cements India's role in global pharma GCC play

Sanofi has expanded its Hyderabad Global Capability Centre, raising capacity to 4,500 employees and strengthening India's position as a key hub for R&D, AI, digital innovation

Two-wheeler makers see split export recovery in October-December quarter

Market-specific recovery patterns drove swings in overseas volumes in Q3

Fortis Healthcare Q3 results: Profit falls 21.8%; revenue up 17.5%

Hospital chain reports ₹193.7 crore net profit in Q3 FY26 amid one-time expense; hospital and diagnostics segments post revenue growth and margin expansion

Alkem MedTech to acquire 55% stake in Occlutech for €99.4 million

Alkem Laboratories' devices arm to acquire controlling stake in Swiss cardiac implant maker, marking entry into global structural heart segment

Torrent Pharma Q3FY26 results: Profit rises 26%; revenue up 17.6%

Ahmedabad-based drugmaker reports Rs 635 crore Q3 profit on strong India, Brazil and US growth; revenues rise 17.6% to Rs 3,303 crore

Mahindra expands Chennai research valley with ₹196 crore investment

Automaker to invest ₹196 crore in expanding Mahindra Research Valley in Chennai, adding advanced R&D and testing facilities and creating 2,000 jobs this year

Doctors flag risks of relying on HbA1c for diabetes diagnosis in India

Doctors warn that heavy reliance on HbA1c for diabetes diagnosis in India may lead to under- or over-diagnosis due to high anaemia and kidney disease burden, urging multiparametric testing

EV retail sales expand in January, with gains across PVs and two-wheelers

India's EV retail market expanded in January 2026, with passenger vehicles and two-wheelers posting strong year-on-year growth amid rising demand, FADA data showed

US-Bangladesh trade agreement unlikely to dent India's auto exports

The US-Bangladesh reciprocal trade pact is unlikely to materially affect India's auto and auto component exports, analysts say, despite tariff concessions and wider market access for Dhaka

French drugmaker Servier bets big on India as key global export hub

French drugmaker to commit €15 million annually to SPC development and exports for cardiometabolic and venous diseases

Eyeing a growth pill: Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

US market remained a drag for Indian pharma in Q3 amid pricing pressure

The US market stayed a weak spot for Indian pharma companies in Q3FY26 amid sustained pricing pressure in generics, heightened competition and product-specific challenges

US-India trade deal offers auto exporters relief, but tariff fog remains

India's auto component exporters may see relief under the interim US-India trade framework, but industry bodies say clarity on Section 232 tariffs and quota rules is needed to gauge gains

JK Tyre and Industries posts record revenue of ₹4,223 crore in Q3FY26

JK Tyre reported its highest-ever quarterly revenue in Q3 FY26 as volumes recovered and raw material costs eased, helping profits rebound sharply from a weak base last year

Alembic to skip first wave of global semaglutide launches, eyes India

Alembic Pharmaceuticals said it will miss the first wave of global generic semaglutide launches but is exploring partnerships for a faster entry into the Indian market

Metropolis Q3FY26 results: Profit jumps 32%, revenue rises nearly 26%

India's second-largest pathology chain reported strong year-on-year profit growth in the December quarter, supported by higher test volumes, preventive care demand and specialised diagnostics

Budget 2026: Customs duty relief to make cancer, rare disease drugs cheaper

A customs duty exemption on select high-cost cancer and rare disease therapies is expected to lower treatment costs for patients while supporting demand for multinational and domestic pharma companies

Budget 2026: India's medical tourism sector gears up for next growth phase

With the medical value tourism market projected to cross ₹1.23 trillion by 2026, industry players see Budget 2026's proposal for regional hubs as a structural boost to India's global healthcare ambiti